biomarkers-market

Biomarkers Market By Product, By Type, By Application, By Disease Indication - Growth, Share, Opportunities & Competitive Analysis, 2024 - 2032

09 May 2023 Format PDF icon PPT icon XLS icon Request Sample

The worldwide biomarkers market is predicted to grow at 12.5% by 2031. Growing expenditure on health care and research & development activities plus enhanced utility of biomarkers for diagnostics are predicted to stimulate the growth of the global biomarkers market. The growth and expansion of the industry will also be supported by the low prices of clinical trials in emerging nations and new initiatives taken by the firms who are into the biomarker research business.

On the other hand, factors like requirement of heavy business investment, low cost-benefit ratio, poorly matched compensation methods and control systems and high price of tests and sample collection & storage are the key factors inhibiting the growth and expansion of the global biomarkers market. Further, fast expansion of the IT sector, rapidly rising world population and growing efforts by scientific community to discover new medicines are few of the drivers stimulating the growth of the global biomarkers market.

Biomarkers are physically occurring genetic materials or molecules which are introduced to the target site or organ to monitor physiological routes of the ailments. They are used as diagnostic means to evaluate the establishment as well the intensity of the ailment. These biomarkers also help doctors in taking accurate medical decisions and assists them in perfectly diagnosing the health of patients. Biomarkers demand and its market growth is projected to enhance further owing to their medical applications in the field of cancer research and treatment. New market entrants in the global biomarkers market is predicted to generate new business growth avenues for the worldwide biomarkers market.

Biomarkers hold substantial significance in the area of drug discovery & development. It offers clarity on the ailment in terms of its ailment epidemiology. So the growing amount of initiatives taken in the field of drug discovery & development is the most substantial market growth driver. Further, growing global occurrence of neurology, cardiology and oncology based ailments and stimulating initiatives taken by regulatory authorities like US food and drug administration will serve as the driver of the worldwide biomarker market.

The global biomarkers market is divided into products, types, applications, disease indications and geographical regions.

The worldwide biomarkers market by products includes Software, Consumables and Services.

The global biomarkers market by types safety biomarkers, validation biomarkers and efficacy biomarkers. Efficacy Biomarkers includes Surrogate Biomarkers, Pharmacodynamic Biomarkers, Predictive Biomarkers and Prognostic Biomarkers.

The worldwide biomarkers market by applications includes disease risk assessment, diagnostics development, personalized medicine and drug discovery & development.

Drug discovery & development section leads the global biomarkers market in market share terms. This section is predicted to retain its leading position during the estimated period. Drug discovery & development carry high significance in the pharmaceuticals sector. The utilization of biomarkers in the procedure of drug discovery & development assist in increasing the procedure and judging failures of medicines or drugs. Such a capability of biomarkers to judge the failure of medicine and drugs saves the incurrence of heavy costs as per the estimates of the US food and drugs administration. Perfect predictions of drug/medicine failures can save up to 100 million US dollars for the drug producers.

The global biomarkers market by disease indications includes immunological disorders, cancer, neurological disorders and heart or cardiovascular disorders.

The cancer section leads the worldwide biomarkers market. High worldwide occurrence of cancer combined with the presence of high level of patient consciousness contributes towards the above described fact. But , the heart disorder section is predicted to be the most profitable section in terms of business growth in future. Rise in occurrence of heart ailments and presence of high unfulfilled medical requirements are few of the stimulators of the worldwide biomarkers market.

The worldwide biomarkers market by geographical regions includes sub continent of North America, European continent, Asia Pacific region and the region of the rest of the world.

The sub continent of North America contributes towards biggest market share of the global biomarkers market. The presence of modern healthcare infrastructure facility, new product launches, availability of good research & development facility, high rate of adoption of modern techniques, entry of new industry players in the business/market sector, wide utilization of biomarkers and incurrence of high per capita expenditure on healthcare activities are the factors expected to contribute towards the growth and development of the biomarkers market in North America. Further, strong development trends in contract research organizations and pharmaceutical firms in this sub continent will add to the growth and expansion of the market in this North American sub continent. This region is predicted to witness a rapid market growth during the forecasted period.

The biomarkers market of Asia Pacific region is predicted to expand at a rapid rate due to growth of key biomarker firms, enhanced expenditure on research & development activities, increase in amount of contract research organizations and fast economic growth witnessed in countries like India and China of this region.

Recent Developments

  • In December 2023, F. Hoffmann-La Roche Ltd. announced that Elecsys beta-amyloid (1-42) CSF II (Abeta42) and Elecsys phospho-Tau (181P) CSF (pTau181) assays had received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and pTau181 assays (used as a pTau181/Abeta42 ratio) measure two biomarkers that are hallmarks of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease.
  • In September 2023, Enzo Biochem launched the AMPIVIEW Gene Expression Platform with products targeting the detection of HPV and SARS-CoV-2.
  • In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched two cardiac biomarker tests: high-sensitivity cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide (NT-proBNP). These gold standard biomarkers support cardiovascular disease management and can help clinicians diagnose heart attacks and manage heart failure better.
  • In May 2021, QIAGEN N.V. (Netherlands) launched the first FDA-approved tissue companion diagnostic, therascreen KRAS RGQ PCR Kit, to identify the KRAS G12C mutation in NSCLC tumors and expand precision medicine options in lung cancer.

The key market players included in the market research report are as follows:

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, QIAGEN N.V., PerkinElmer, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., Charles River Laboratories International, Inc., Eurofins Scientific and Other Notable Players.

The key industry participants in the worldwide biomarkers market are predicted to face tough competition from new market players in future. So it is necessary for the most prominent players of the industry to stay abreast with the new technological changes and adapt to fast changing business trends and industrial trends in order to gain competitive advantage over their competitors in this business/market sector.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Biomarkers market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Biomarkers market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Product
  • Consumables
  • Services
  • Software

Type
  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamics Biomarkers
  • Prognostic Biomarkers
  • Validation Biomarkers

Application
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

Disease Indication
  • Cancer
  • Infectious Diseases
  • Immune Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Biomarkers market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Biomarkers market?
  • Which is the largest regional market for Biomarkers market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Biomarkers market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Biomarkers market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports